A newly identified mechanism lends credence to the idea that MS may be treatable by targeting EBV-infected B-cells, a study found.
Kanazawa University, in collaboration with Osaka University and the National Institutes for Quantum Science and Technology, ...
A deep dive into the Fc–FcR axis as a therapeutic anchor in autoimmune disease, examining immune signaling and drug ...
The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
Results from two clinical trials on ianalumab for Sjögren disease show favorable safety and adverse event outcomes, ...
Novartis NVS announced that the FDA granted Breakthrough Therapy designation to its pipeline candidate, ianalumab for the ...
The FDA has granted breakthrough therapy designation to Novartis’ ianalumab for Sjögren’s disease, according to a press release from the manufacturer.In its statement, Novartis said it plans to submit ...
Rockville, Maryland Friday, January 9, 2026, 10:00 Hrs [IST] ...
Ianalumab receives FDA Breakthrough Therapy status for Sjögren disease following positive findings from two phase 3 clinical trial programs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results